Bionano Announces Presentations Featuring OGM Utility Across Blood Cancer Research at the American Society of Hematology (ASH) Annual Meeting
- A platform presentation will feature Dr.
Enze Liufrom the Indiana University School of Medicinesharing findings from a study on the use of optical genome mapping (OGM) to detect structural variants (SVs) in multiple myeloma
- Thirteen scientific posters featuring results from OGM applications in myeloid cancers, acute lymphoblastic leukemia (ALL), myelodysplastic syndromes (MDS) and hematological malignancy research will be presented at the conference
ASH’s Annual Meeting brings together industry, medical, and academic professionals to discuss advances in the field of blood disease. The ASH conference will be held
13 posters featuring results from OGM applications in cytogenetic research will be presented at the conference. Unless otherwise noted below, posters will be available to view at the
Scientific presentations and poster sessions from Bionano and collaborators include:
|Partner Gene Associated Trinary Fusion and Orchestration of Multiple Molecular Events in Acute Promyelocytic Leukemia with Variant Rara Fusion Genes
|Deciphering the Structural Variants in B Cell Acute Lymphoblastic Leukemia by Optical Genome Mapping
|Optical Genome Mapping for Genome-Wide Structural Variation Analysis in Hematologic Malignancies: A Prospective Study Demonstrates Additional Findings Compared to Standard-of-Care (SOC) Cytogenomic Methods
|Multiomic Characterization of Myelodysplastic Neoplasms (MDS) with Micromegakaryocytes Highlights the Role of EZH2-RUNX1 Deregulation in Disease Hysiopathology and Response to
|Optical Genomic Mapping Provides Unique Findings in Various Types of Myeloid Neoplasms
|Comprehensive Characterization of Evolution of Genomic Complexity by Structural Variant and Mutational Profiling in Myelodysplastic Syndrome Patients with Hypomethylating Agent Failure
|Enhancing Cytogenetic Diagnostics: Incorporating Optical Genome Mapping in the Laboratory Routine
|Optical Genome Mapping Allows Detection and Characterization of Cytogenetically Cryptic Oncogenic Fusions in Pediatric Acute Myeloid Leukemia
|Assessment of Optical Genome Mapping for Front-Line Diagnostic Evaluation of Acute Leukemia: A Canadian Single-Center Evaluation of Added Yield in 69 Informative Cases
|Optical Genome Mapping Combined with High-Throughput Sequencing Is Effective for the Diagnostic and Prognostic Genomic Classification of Acute Myeloid Leukemia and Myelodysplastic Neoplasms
|Platinum Talen-Mediated Knock-in of Single-Stranded DNA Templates Facilitates Manufacturing of Clinical-Scale Non-Virally Gene-Edited T Cells from Peripheral Blood
|Optical Genome Mapping Provides New Molecular Insights in High-Risk Mantle Cell Lymphoma: A Lysa Study
|Deciphering the Structural Variants in Acute Myeloid Leukemia and Myelodysplastic Neoplasms by Optical Genome Mapping
|Unraveling Diverse Mechanisms of Complex Structural Variant Interactions through Multiomic Data in Multiple Myeloma
“The broad range of presentations on the use of OGM for hematological malignancy research at ASH this year illustrate the importance of OGM in an area of medical research that can really improve patient care in the long run. The ASH conference brings together thousands of clinicians, scientists and industry members working to conquer blood diseases, and we are pleased that OGM and its role in these research areas will be so well-represented at the meeting,” stated Erik Holmlin, PhD, president and chief executive officer of Bionano.
More details on the conference can be found here.
Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. Through its Lineagen, Inc. d/b/a Bionano Laboratories business, the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. The Company also offers an industry-leading, platform-agnostic software solution, which integrates next-generation sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view. The Company additionally offers nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. For more information, visit www.bionano.com, www.bionanolaboratories.com or www.purigenbio.com.
Unless specifically identified, Bionano’s OGM products are for research use only and not for use in diagnostic procedures.
Forward-Looking Statements of Bionano
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “potential,” “will,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, OGM’s utility for research applications in myeloid cancer, hematological malignancy, leukemia and blood disorders, and the utility of OGM for research in the areas reported in the presentations given and the posters made available at ASH’s 2023 annual meeting, and the growth and adoption of OGM for use in research applications in myeloid cancer, hematological malignancy, leukemia and blood disorders. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: global and macroeconomic events, such as recent and potential bank failures, potential resurgences of COVID-19 or other pandemic inducing diseases, the ongoing conflicts between
+1 (858) 888-7610
+1 (858) 888-7625
Source: Bionano Genomics